DK0436332T3 - Polyaminer, der er anvendelige som antagonister for excitatorisk-aminosyre-neurotransmittere - Google Patents

Polyaminer, der er anvendelige som antagonister for excitatorisk-aminosyre-neurotransmittere

Info

Publication number
DK0436332T3
DK0436332T3 DK90313663.8T DK90313663T DK0436332T3 DK 0436332 T3 DK0436332 T3 DK 0436332T3 DK 90313663 T DK90313663 T DK 90313663T DK 0436332 T3 DK0436332 T3 DK 0436332T3
Authority
DK
Denmark
Prior art keywords
amino acid
neurotransmitters
excitatory
antagonists
polyamines useful
Prior art date
Application number
DK90313663.8T
Other languages
Danish (da)
English (en)
Inventor
Nicholas Alex Saccomano
Robert Alfred Volkmann
Original Assignee
Pfizer
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Nps Pharma Inc filed Critical Pfizer
Application granted granted Critical
Publication of DK0436332T3 publication Critical patent/DK0436332T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyamides (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK90313663.8T 1990-01-02 1990-12-14 Polyaminer, der er anvendelige som antagonister for excitatorisk-aminosyre-neurotransmittere DK0436332T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46020790A 1990-01-02 1990-01-02
US07/560,699 US5037846A (en) 1990-01-02 1990-07-31 Indolyl-3 polyamines and their use as antagonists of excitatory amino acid neurotransmitters

Publications (1)

Publication Number Publication Date
DK0436332T3 true DK0436332T3 (da) 1996-03-11

Family

ID=27039601

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90313663.8T DK0436332T3 (da) 1990-01-02 1990-12-14 Polyaminer, der er anvendelige som antagonister for excitatorisk-aminosyre-neurotransmittere

Country Status (23)

Country Link
US (1) US5037846A (de)
EP (1) EP0436332B1 (de)
JP (1) JPH0714913B2 (de)
KR (1) KR930007250B1 (de)
CN (1) CN1053059A (de)
AT (1) ATE133941T1 (de)
AU (2) AU619700B2 (de)
CA (1) CA2033480C (de)
DE (1) DE69025305T2 (de)
DK (1) DK0436332T3 (de)
ES (1) ES2083439T3 (de)
FI (1) FI93644C (de)
GR (1) GR3019487T3 (de)
HU (1) HUT56063A (de)
IE (1) IE70757B1 (de)
IL (1) IL96793A0 (de)
MY (1) MY104588A (de)
NO (1) NO173733C (de)
NZ (1) NZ236550A (de)
PH (1) PH27608A (de)
PL (1) PL165647B1 (de)
PT (1) PT96389A (de)
YU (1) YU247590A (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227397A (en) * 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
US5037846A (en) * 1990-01-02 1991-08-06 Pfizer Inc. Indolyl-3 polyamines and their use as antagonists of excitatory amino acid neurotransmitters
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US5677288A (en) * 1991-05-15 1997-10-14 Cypros Pharmaceutical Corporation Use of aminoglycosides to protect against excitotoxic neuron damage
BR9206403A (pt) * 1991-08-23 1994-12-27 Pfizer Aril-poliaminas sintéticas como antagonistas de neurotransmissores aminoácidos excitadores
US5185369A (en) * 1991-08-23 1993-02-09 Pfizer Inc. Synthetic heteroaryl polyamines as excitatory amino acid neurotransmitter antagonists
US5763568A (en) * 1992-01-31 1998-06-09 Zeneca Limited Insecticidal toxins derived from funnel web (atrax or hadronyche) spiders
US6750244B2 (en) 1993-02-08 2004-06-15 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7087765B2 (en) 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6211245B1 (en) 1993-02-08 2001-04-03 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE69434889D1 (de) 1994-02-08 2007-01-11 Nps Pharma Inc An einer neuen Stelle von Rezeptorabhängigen Kalziumkanälen wirkende Verbindungen zur Behandlung von neurologischen Erkrankungen
US5688764A (en) * 1995-02-17 1997-11-18 Nps Pharmaceuticals, Inc. Insecticidal peptides from spider venom
US5874298A (en) * 1995-02-17 1999-02-23 Nps Pharmaceuticals, Inc. Insecticidal toxins from Bracon hebetor nucleic acid encoding said toxin and methods of use
US5674846A (en) * 1996-09-04 1997-10-07 Nps Pharmaceuticals, Inc. Insecticidal peptides from Segestria sp. spider venom
WO1998036743A1 (en) * 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
AU2003231670B2 (en) * 1997-10-27 2006-06-08 Slil Biomedical Corporation Methods for modulating macrophage proliferation using polyamine analogs
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
WO2002053519A2 (en) * 2001-01-08 2002-07-11 Mediquest Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
JP2005510524A (ja) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
EP1448183A2 (de) * 2001-11-16 2004-08-25 ALS Therapy Development Foundation, Inc. Behandlung von neurodegenerativen erkrankungen durch modulieren des polyaminenbiosynthesewegs
BRPI0517551A (pt) * 2004-10-04 2008-10-14 Cellgate Inc análogos de poliamina como agentes terapêuticos para doenças oculares
CN101300004B (zh) * 2005-09-23 2013-08-21 帕瑟洛吉卡有限公司 使用多胺类似物治疗病毒感染的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
IT1206078B (it) * 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
US4950739A (en) * 1988-02-10 1990-08-21 New York University Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
US5037846A (en) * 1990-01-02 1991-08-06 Pfizer Inc. Indolyl-3 polyamines and their use as antagonists of excitatory amino acid neurotransmitters

Also Published As

Publication number Publication date
NO173733C (no) 1994-01-26
ES2083439T3 (es) 1996-04-16
NO905616L (no) 1991-07-03
KR910014123A (ko) 1991-08-31
US5037846A (en) 1991-08-06
FI906466L (fi) 1991-07-03
NZ236550A (en) 1992-05-26
PL165647B1 (pl) 1995-01-31
AU1592692A (en) 1992-07-09
IE70757B1 (en) 1996-12-30
YU247590A (sh) 1993-10-20
CA2033480A1 (en) 1991-07-03
PH27608A (en) 1993-08-18
FI906466A0 (fi) 1990-12-31
NO905616D0 (no) 1990-12-28
FI93644B (fi) 1995-01-31
EP0436332A2 (de) 1991-07-10
MY104588A (en) 1994-04-30
IE904734A1 (en) 1991-07-17
JPH04210677A (ja) 1992-07-31
GR3019487T3 (en) 1996-07-31
DE69025305T2 (de) 1996-06-27
AU619700B2 (en) 1992-01-30
AU640565B2 (en) 1993-08-26
CA2033480C (en) 1995-11-21
PT96389A (pt) 1991-10-15
FI93644C (fi) 1995-05-10
HUT56063A (en) 1991-07-29
KR930007250B1 (ko) 1993-08-04
PL288490A1 (en) 1991-12-16
DE69025305D1 (de) 1996-03-21
EP0436332A3 (en) 1991-09-25
AU6856190A (en) 1991-07-04
NO173733B (no) 1993-10-18
JPH0714913B2 (ja) 1995-02-22
IL96793A0 (en) 1991-09-16
ATE133941T1 (de) 1996-02-15
CN1053059A (zh) 1991-07-17
EP0436332B1 (de) 1996-02-07

Similar Documents

Publication Publication Date Title
DK0436332T3 (da) Polyaminer, der er anvendelige som antagonister for excitatorisk-aminosyre-neurotransmittere
FI112471B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten hydroksietyyliaminosulfoniamidien valmistamiseksi
CA2015505A1 (en) Polyamines and polypeptides useful as antagonists of excitatory amino acid neurotransmitters and/or as blockers of calcium channels
FI91072C (fi) Menetelmä terapeuttisesti aktiivisten heterosyklisten peptidien valmistamiseksi ja niiden valmistuksessa käyttökelpoisia välituotteita
DE69226822D1 (de) Diastereomeres Salz von optisch aktiver Chinolinmevalonsäure
NO178969C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte kinazolinoner
OA09982A (fr) Derives heterocycliques leur procede de production et composition pharmaceutique les contenant
MX9403286A (es) Acido valerico substituido.
DE3875792D1 (de) Neues herbizid, seine herstellung und seine verwendung.
FI895185A0 (fi) Mevalonolaktoner av tienopyridintyp.
FI101301B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahydroatsepiinijohdannaisten valmistamiseksi
NO885313D0 (no) Nye forbindelser.
FI893682A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,2,5-ditiatsosiinijohdannaisten valmistamiseksi
PT89492A (pt) Processo de preparacao de novos derivados de tioformamida terapeuticamente activos
NO20033880L (no) Fremgangsmåte for fremstilling av optiske aktive propoksyanilinderivater
ATE110730T1 (de) Verfahren zur herstellung von cephalosporinen.
DE68903188D1 (de) Acylsulfonamid-derivate von alpha-carbocyclyltoluylsaeuren und ihre verwendung als leukotrienantagonisten.